BUSINESS COMBINATIONS (Details 10)	12 Months Ended			1 Months Ended	10 Months Ended	12 Months Ended					1 Months Ended			12 Months Ended
	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)	Dec. 31, 2009 USD ($)	Feb. 28, 2011 PharmaSwiss S.A. USD ($)	Dec. 31, 2011 PharmaSwiss S.A. USD ($)	Dec. 31, 2011 PharmaSwiss S.A. USD ($) Y	Dec. 31, 2011 PharmaSwiss S.A. EUR (€)	Mar. 10, 2011 PharmaSwiss S.A. USD ($)	Mar. 10, 2011 PharmaSwiss S.A. EUR (€)	Feb. 28, 2011 PharmaSwiss S.A. EUR (€)	Mar. 31, 2011 PharmaSwiss S.A. Maximum area country	Mar. 10, 2011 PharmaSwiss S.A. Maximum USD ($)	Mar. 10, 2011 PharmaSwiss S.A. Maximum EUR (€)	Dec. 31, 2011 PharmaSwiss S.A. Partner relationships Y	Dec. 31, 2011 PharmaSwiss S.A. Product brands Y	Mar. 10, 2011 PharmaSwiss S.A. Amounts Recognized as of Acquisition Date (as previously reported) USD ($)	Mar. 10, 2011 PharmaSwiss S.A. Amounts Recognized as of Acquisition Date (as previously reported) Partner relationships USD ($)	Mar. 10, 2011 PharmaSwiss S.A. Amounts Recognized as of Acquisition Date (as previously reported) Product brands USD ($)	Mar. 10, 2011 PharmaSwiss S.A. Adjustments Measurement Period Adjustments USD ($)	Mar. 10, 2011 PharmaSwiss S.A. Adjustments Measurement Period Adjustments Product brands USD ($)	Dec. 31, 2011 PharmaSwiss S.A. Amounts Recognized (as adjusted) USD ($)	Dec. 31, 2011 PharmaSwiss S.A. Amounts Recognized (as adjusted) Partner relationships USD ($)	Dec. 31, 2011 PharmaSwiss S.A. Amounts Recognized (as adjusted) Product brands USD ($)
Business Combinations
Cash consideration								$ 491,200,000	€ 353,100,000
Fair value of contingent payments								27,500,000
Potential contingent consideration payment					13,000,000	13,000,000	10,000,000					41,700,000	30,000,000
Acquisition-related contingent consideration	(10,986,000)					13,200,000
Notional amount of foreign currency forward-exchange contract purchased										130,000,000
Gain on settlement of foreign currency forward-exchange contract				5,100,000
Foreign exchange loss recognized on amount bought to finance business acquisition				2,400,000
Remaining foreign currency consideration used to finance transaction of business combination										220,000,000
Net foreign exchange gain recognized in earnings	26,551,000	574,000	507,000			2,700,000
Number of therapeutic areas in which broad product portfolio is offered											7
Number of countries of operation											19
Assets acquired and liabilities assumed
Cash and cash equivalents																43,940,000					43,940,000
Accounts receivable																63,509,000			(1,880,000)		61,629,000
Inventories																72,144,000			(1,825,000)		70,319,000
Other current assets																14,429,000					14,429,000
Property, plant and equipment																9,737,000					9,737,000
Identifiable intangible assets																202,071,000	130,183,000	71,888,000	7,169,000	7,169,000	209,240,000	130,183,000	79,057,000
Other non-current assets																3,122,000					3,122,000
Current liabilities																(46,866,000)			826,000		(46,040,000)
Deferred income taxes, net																(18,176,000)			11,568,000		(6,608,000)
Other non-current liabilities																(720,000)					(720,000)
Total identifiable net assets																343,190,000			15,858,000		359,048,000
Goodwill																171,105,000			(11,445,000)		159,660,000
Total fair value of consideration transferred																514,295,000			4,413,000		518,708,000
Fair value of accounts receivable acquired								61,600,000
Gross contractual amount of trade accounts receivable acquired								66,800,000
Expected uncollectible of trade accounts receivable acquired								5,200,000
Entry to record inventory at its estimated fair value								18,200,000
Estimated weighted-average useful life (in years)						7								7	9
Acquisition-related costs	32,964,000	38,262,000	5,596,000		2,100,000
Acquisition-related integration and restructuring costs						3,500,000
Revenues of acquiree since acquisition date					199,900,000
Earnings of acquiree since acquisition date					(23,500,000)
Effects of the acquisition accounting adjustments					41,600,000
Acquisition-related integration costs						$ 5,600,000